Toward the individualization of lung cancer therapy

Cancer

Volumn 113, Issue 7, 2008, Pages 1760-1767

  Anguiano, Ariel ^a   Nevins, Joseph R ^a   Potti, Anil ^a  

^a DUKE UNIVERSITY   (United States)

Author keywords

Chemotherapy prediction; Expression signature; Improved prognosis; Pathway prediction

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; PACLITAXEL; TOPOTECAN;

CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; DNA MICROARRAY; EARLY CANCER; GENE EXPRESSION PROFILING; GENOMICS; HUMAN; LUNG CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CARCINOMA, NON-SMALL-CELL LUNG; GENE EXPRESSION PROFILING; HUMANS; LUNG NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 53949088908     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23644     Document Type: Review

References (65)

1. Herbst RS, Bajorin DF, Bleiberg H, et al. Clinical Cancer Advances 2005: major research advances in cancer treatment, prevention, and screening-a report from the American Society of Clinical Oncology. J Clin Oncol. 2006;24:190-205.
2. Breathnach OS, Freidlin B, Conley B, et al. Twenty-two years of phase III trials for patients with advanced nonsmall-cell lung cancer: sobering results. J Clin Oncol. 2001;19:1734-1742.
3. Minna JD, Gazdar AF, Sprang SR, Herz J. Cancer. A bull's eye for targeted lung cancer therapy. Science. 2004;304:1458-1461.
4. Spira A, Ettinger DS. Multidisciplinalry management of lung cancer. N Engl J Med. 2004;350:379-392.
5. Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355:479-485.
6. Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710-1717.
7. Nesbitt JC, Putnam JB Jr, Walsh GL, Roth JA, Mountain CF. Survival in early-stage non-small cell lung cancer. Ann Thorac Surg. 1995;60:466-472.
8. Mountain CF. The new international staging system for lung cancer. Surg Clin North Am. 1987;67:925-935.
9. D'Amico TA, Massey M, Hemdon JEd, Moore MB, Harpole DH Jr. A biologic risk model for stage 1 lung cancer: immunohistochemical analysis of 408 patients using 10 molecular markers. J Thorac Cardiovasc Surg. 1999; 117:736-743.
10. Brundage MD, Davies D, Mackillop WJ. Prognostic factors in non-small cell lung cancer: a decade of progress. Chest. 2002;122:1037-1057.
11. Meyerson M, Carbone DE Genomic and proteomic profiling of lung cancers: lung cancer classification in the age of targeted therapy. J Clin Oncol. 2005;23:3219-3226.
12. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small cell lung cancer. N Engl J Med. 2005;352:2589-2597.
13. Douillard J, Rosell R, Delena M, Legroumellec A, Torres A, Carpagnano F. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): final results after 70-month median followup. J Clin Oncol. 2005;21(14S):7013.
14. Kato H, Ichinose Y, Ohta M, et al. Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uraciltegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713-1721.
15. Strauss GM, Herndon JE, Maddaus MA, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage 1B non-small cell lung cancer. J Clin Oncol. 2004;22(14S):7019.
16. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004; 350:351-360.
17. Tonon G, Wong KK, Maulik G, et al. High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A. 2005;102:9625-9630.
18. Schneider PM, Praeuer HW, Stoeltzing O, et al. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer. Br J Cancer. 2000;83:473-479.
19. Berrar D, Sturgeon B, Bradbury I, Downes CS, Dubitzky W. Survival trees for analyzing clinical outcome in lung adenocarcinomas based on gene expression profiles: identification of neogenin and diacylglycerol kinase alpha expression as critical factors. J Comput Biol. 2005;12:534-544.
20. Ju Z, Kapoor M, Newton K, et al. Golbal detection of molecular changes reveals concurrent alteration of several biological pathways in non-small cell lung cancer cells. Mol Genet Genomics. 2005;28:1-14.
21. Beer DG, Kardia SLR, Huang CC, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med. 2002;8:816-824.
22. Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A. 2001;98:13790-13795.
23. Wigle DA, Jurisica I, Radulovich N, et al. Molecular profiling of non-small cell lung cancer and correlation with disease-free survival. Cancer Res. 2002;62:3005-3008.
24. Kikuchi T, Daigo Y, Katagiri T, et al. Expression profiles of non-small cell lung cancers on cDNA microarrays: identification of genes for prediction of lymph-node metastasis and sensitivity to anti-cancer drugs. Oncogene. 2003;22:2192-2205.
25. Garber ME, Troyanskaya OG, Schluens K, et al. Diversity of gene expression in adenocarcinoma of the lung. Proc Natl Acad Sci U S A. 2001;8:13784-13789.
26. Yanaihara N, Caplen N, Bowman E, et al. Unique micro- RNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell. 2006;9:189-198.
27. Dressman HK, Bild A, Garst J, Harpole D, Potti A. Genomic signatures in non small cell lung cancer: targeting the targeted therapies. Curr Oncol Rep. 2006;8:252-257.
28. Chen G, Gharib TG, Wang H, et al. Protein profiles associated with survival in lung adenocarcinoma. Proc Natl Acad Sci U S A. 2003;100:13537-13542.
29. Bild A, Yao G, Chang JT, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature. 2006;439:353-357.
30. Potti A, Mukherjee S, Prince R, et al. A genomic strategy to refine prognosis in non-small cell lung carcinoma. N Engl J Med. 2006;355:570-580.
31. Sparano JA. TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006;7:347-350.
32. Piccart-Gebhart MJ, Sotiriou C. Adjuvant chemotherapyyes or no? Prognostic markers in early breast cancer. Ann Oncol. 2007;(suppl 12):xii2-xii7.
33. Bogaerts J, Cardoso F, Buyse M, et al. TRANSBIG consortium. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006;3:540-551.
34. Potti A, Lancaster JM, Dressman HK, et al. A genomic strategy to guide the use of chemotherapeutic drugs in solid tumors. Nat Med. 2006;12:1294-1300.
35. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet. 2003;362:362-369.
36. Ayers M, Symmans WF, Stec J, et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J Clin Oncol. 2004;22:2284-2293.
37. Rouzier R, Pusztai L, Delaloge S, et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J Clin Oncol. 2005;23:8331-8339.
38. Peintinger F, Anderson K, Mazouni C, et al. Thirty-gene pharmacogenomic test correlates with residual cancer burden after preoperative chemotherapy for breast cancer. Clin Cancer Res. 2007;13:4078-4082.
39. Rouzier R, Perou CM, Symmans WF, et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res. 2005;11:5678-5685.
40. Paik S, Tang G, Shak S, et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol. 2006;24:3726-3734.
41. Gianni L, Zambetti M, Clark K, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol. 2005;23:7265-7277.
42. Cario G, Stanulla M, Fine BM, et al. Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia. Blood. 2005;105:821-826.
43. Lugthart S, Cheok MH, den Boer ML, et al. Identification of genes associated with chemotherapy crossresistance and treatment response in childhood acute lymphoblastic leukemia. Cancer Cell. 2005;7:375-386.
44. Holleman A, Cheok MH, den Boer ML, et al. Gene expression patterns in drug resistant acute lymphoblastic leukemia cells and response to treatment. N Engl J Med. 2004; 351:533-542.
45. Beesley AH, Cummings AJ, Freitas JR, et al. The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure. Br J Haematol. 2005;131:447-456.
46. Talby L, Chambost H, Roubaud MC, et al. The chemosensitivity to therapy of childhood early B acute lymphoblastic leukemia could be determined by the combined expression of CD34, SPI-B and BCR genes. Leuk Res. 2006;30:665-676.
47. Heuser M, Wingen LU, Steinemann D, et al. Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica. 2005;90:1484-1492.
48. Eisele L, Klein-Hitpass L, Chatzimanolis N, et al. Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. Acta Haematol. 2007;117:8-15.
49. Okutsu J, Tsunoda T, Kaneta Y, et al. Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther. 2002;1:1035-1042.
50. Mintz MB, Sowers R, Brown KM, et al. An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res. 2005;65:1748-1754.
51. Cleator S, Tsimelzon A, Ashworth A, et al. Gene expression patterns for doxorubicin (Adriamycin) and cyclophosphamide (Cytoxan) (AC) response and resistance. Breast Cancer Res Treat. 2006;95:229-233.
52. Durbecq V, Paesmans M, Cardoso F, et al. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther. 2004;3:1207-1214.
53. Sotiriou C, Powles TJ, Dowsett M, et al. Gene expression profiles derived from fine needle aspiration correlate with response to systemic chemotherapy in breast cancer. Breast Cancer Res. 2002;4:R3.
54. Bachvarov D, L'esperance S, Popa I, Bachvarova M, Plante M, Tetu B. Gene expression patterns of chemoresistant and chemosensitive serous epithelial ovarian tumors with possible predictive value in response to initial chemotherapy. Int J Oncol. 2006;29:919-933.
55. Dressman HK, Berchuck A, Chan G, et al. An integrated genomic-based approach to individualized treatment of patients with advanced stage ovarian cancer. J Clin Oncol. 2007;25:517-525.
56. Moriyama M, Hoshida Y, Kato N, et al. Genes associated with human hepatocellular carcinoma cell chemosensitivity to 5-fluorouracil plus interferon-alpha combination chemotherapy. Int J Oncol. 2004;25:1279-1287.
57. Akada M, Crnogorac-Jurcevic T, Lattimore S, et al. Intrinsic chemoresistance to gemcitabine is associated with decreased expression of BNIP3 in pancreatic cancer. Clin Cancer Res. 2005;11:3094-3101.
58. Hsu DS, Balakumaran BS, Acharya CR, et al. Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol. 2007;25:4350-4357.
59. Sweet-Cordero A, Mukherjee S, Subramanian A, et al. An oncogenic KRAS2 expression signature identified by crossspecies gene expression analysis. Nat Genet. 2005;37:48-54.
60. Adler AS, Lin M, Horlings H, Nuyten DS, van de Vijver MJ, Chang HY. Genetic regulators of large-scale transcriptional signatures in cancer. Nat Genet. 2006;38:421-430.
61. Zuber I, Tchernitsa OI, Hinzmann B, et al. A genome-wide survey of RAS transformation targets. Nat Genet. 2000;24:144-152.
62. Tchernitsa OI, Zuber J, Sers C, et al. Gene expression profiling of fibroblasts resistant toward oncogene-mediated transformation reveals preferential transcription of negative growth regulators. Oncogene. 1999;18:5448-5454.
63. Vasseur S, Malicet C, Calvo EL, et al. Gene expression profiling by DNA microarray analysis in mouse embryonic fibroblasts transformed by rasV12 mutated protein and the E1A oncogene. Mol Cancer. 2003;2:19.
64. Chng WJ, Kumar S, Vanwier S, et al. Molecular dissection of hyperdiploid multiple myeloma by gene expression profiling. Cancer Res. 2007;67:2982-2989.
65. Shaughnessy JD, Zhan F, Burington BE, et al. A validated gene expression model of high risk multiple myteloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109:2276-2284.